News

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah® (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Read more on Science Daily »
Today at the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, researchers will announce findings from four studies that could greatly expand access to both curative and supportive treatments for individuals living with sickle cell disease…
Read more on American Society of Hematology »
Today during the 60th American Society of Hematology Annual Meeting and Exposition in San Diego, researchers will present the results of four large trials that evaluate promising new treatment options for patients with several types of malignant and non-cancerous blood…
Read more on American Society of Hematology »
Chimeric antigen receptor (CAR) T-cell therapies have quickly shifted the treatment paradigm for many people with several types of aggressive blood cancers, in whom treatment options have been woefully limited.
Read more on American Society of Hematology »
ASH will recognize Senator Cory Booker (D-NJ) and Director of the Division of Hematology Products at the U.S. Food and Drug Administration (FDA) Ann Farrell, MD, for their outstanding leadership in support of biomedical research and hematology.
Read more on American Society of Hematology »
Clinical trial results show a 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka…
Read more on Science Daily »
Researchers have shown that the number of mutations in healthy and leukemic blood stem cells does not differ. Rather the location of the mutations in the DNA is relevant. Using the mutation patterns in the hematopoietic stem and progenitor cells…
Read more on Science Daily »
Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue, suggesting manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.
Read more on American Society of Hematology »
ASH today announced the recipients of its 2019 Scholar Awards. One of ASH’s most prestigious award programs, the ASH Scholar Awards financially support fellows and junior faculty dedicated to careers in hematology research as they transition from training programs to…
Read more on American Society of Hematology »
Today, ASH announced the results of their collective efforts – the 2018 ASH Clinical Practice Guidelines on Venous Thromboembolism – in a press event timed to the publication of the first six chapters in the Society’s peer-reviewed journal Blood Advances.
Read more on American Society of Hematology »
The American Society of Hematology today announced the names of 22 hematologists and medical professionals from developing countries selected to participate in the 2018 ASH Visitor Training Program.
Read more on American Society of Hematology »
Researchers have discovered that breast tumors can boost their growth by recruiting stromal cells originally formed in the bone marrow. The study reveals that the recruitment of bone marrow-derived fibroblasts lowers the odds of surviving breast cancer, but suggests that…
Read more on Science Daily »
The American Society of Hematology has established the ASH Research Collaborative (ASH RC), a mission-focused nonprofit organization that will foster collaborative partnerships to accelerate progress in hematology, with the goal of improving the lives of people affected by blood diseases.
Read more on American Society of Hematology »
A triple therapy combining two immune checkpoint inhibitors (ICPIs) with the standard-of-care chemotherapy, a hypomethylating agent called azacitidine, has shown promising results for treatment of relapsed or refractory acute myeloid leukemia (AML), according to findings from a Phase II study.
Read more on Science Daily »
A new study shows that cancer stem cells switch from metabolizing sugar to metabolizing protein. Clinical trial based on this observation may revolutionize care for older adults with acute myeloid leukemia.
Read more on Science Daily »
A combination of the standard-of-care chemotherapy drug known as azacitidine, with nivolumab, an immune checkpoint inhibitor, demonstrated an encouraging response rate and overall survival in patients with relapsed or refractory acute myeloid leukemia, according to new findings.
Read more on Science Daily »
ASH is pleased to recognize the following trainees with the highest-scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow at the 60th ASH Annual Meeting, December 1-4 in San Diego.
Read more on American Society of Hematology »
Researchers have uncovered an association between RNA abnormalities and multiple myeloma progression. The findings offer novel insights for new, effective therapeutic strategies to be developed.
Read more on Science Daily »
Skeletal stem cells are valuable because it's thought they can heal many types of bone injury, but they're difficult to find because researchers don't know exactly what they look like or where they live.
Read more on Science Daily »